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Abstract
Asthma is defined as the chronic inflammation of the large airways that is characterized by reversible airflow
obstruction and airway hyper-responsiveness. On the other hand, Chronic Obstructive Pulmonary Disease (COPD)
is a chronic inflammation that is marked by progressive and irreversible airflow obstruction. Both conditions are
manifested by symptoms of wheezing, coughing, and shortness of breath. Similarity in symptoms between these two
conditions could lead to misdiagnosis and mistreatment. Although inflammation is present in both conditions, there
are some marked differences. The main difference is that inflammation in asthma is an IgE mediated and involves
the release of histamine while it is absent in the case of COPD. There is now a new trend for measuring the content
of exhaled nitric oxide as a marker for assessing airway inflammation and especially for asthma diagnosis and
monitoring. This study aimed at utilizing biomarkers to differentiate between the different types of respiratory
inflammations. In this study, 23 patients with asthma, 20 with allergic rhinitis, 10 with COPD, and 17 healthy controls
were recruited into the study at a local hospital clinic and assessed based on the level of their exhaled nitric oxide
(eNO), serum specific IgE antibodies, and relative blood eosinophilia count. The results demonstrated that the many
asthmatics (74%) had high eNO levels, while only 25% of patients with allergic rhinitis, 10% of those with COPD,
and 6% of the healthy individuals similarly had elevated eNO levels. The results confirmed the fact that exhaled nitric
oxide could be an effective parameter for differentiating asthma from other allergic diseases (e.g. allergic rhinitis)
and other respiratory inflammations (COPD).
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Introduction
Allergic diseases (asthma, rhinitis, and eczema/dermatitis) could be
atopic and non-atopic. Atopy is the genetic contribution or the
tendency for the development of allergic diseases [1]. It is
characterized by the genetic predisposition for IgE production in
response to exposure to inhalant or food allergens. The risk of a child
developing allergic diseases is 20% if both parents are not affected, but
the risk increases with a single defective parent to be 25%-30% and
50-75% if both is allergic [2].
Both environmental and genetic factors contribute to the
development of an allergic phenotype. Evidence for genetic influence
in the etiology of allergy was first established through twin studies. In
1971, Edfors- lubs studied 7000 Swedish twin pairs and the results for
monozygotic versus dizygotic were as the following: asthma 19% vs.
4.9%, rhinitis 21.4% vs. 13.6%, and eczema 15.4% vs. 4.5%, respectively
[3]. As there are many molecules involved in the inflammatory
response, scientists were able to identify more than 100 genes causing
asthma and other allergic diseases [4]. The genome wide search
approach has established an association between allergic
manifestations and markers on 14 pairs of chromosomes such as 1, 2,
3, 5, 6, 7, 9, 11, 12, 13, 14, 16, 17, 19 [5]. The expression of certain
Human Leukocyte Antigen (HLA) haplotype corresponds to the
exhibition of a certain clinical phenotype. For example, asthmatics
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have the haplotype HLA B7, SC31, DR2 while allergic rhinitis (AR)
patients have the haplotype HLA B8, SC01, DR3 [6]. Environmental
factors such as air borne allergens, air pollutants, and microbial
antigens are also considered to be a risk factor for the development of
allergic diseases. Thus, allergic phenotypes are the result of complex
interactions between genetics and the environment [7,8].
Air pollutants can contribute to the etiology or severity of allergic
diseases. Environmental or air pollutants are classified into primary or
secondary, based on their composition whether they are gases or
particulate matter (PM), and location (indoors or outdoors) [9].
Primary agents are those directly released into the atmosphere such as
SO2, NOx, and CO2 while those resulting from interaction with other
compounds such as ozone are called secondary pollutants. The main
source for outdoor air pollutants production is motor vehicles,
industry, and energy generating facilities and that for indoor
pollutants is fuel or wood burning stoves. Emissions from car exhaust
are made of volatile organic compounds, PM, and poisonous gases
such as CO, CO2, SO2, NOx.NO2 is a toxic gas forming the
photochemical smog with its ability to also form acid rain. NO2
concentrations are elevated in the center of cities and low in the rural
areas. On the other hand, ozone levels are high away from the city
center and low at the center because of its ability to react with NO
forming NO2. People with asthma or COPD get sensitized to lower
doses of NOx resulting in increased bronchial hyper-reactivity [9].
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Diagnosis of Allergy
The diagnosis of the previous allergic conditions requires many
tests. Skin tests especially skin prick tests are widely used in clinical
practice. An aqueous solution of common inhaled allergens such as
HDM, pollen, cat dander, and dog hair, occupational allergens
(ammonium persulphate, platinum salts, antibiotics, and latex), and
food allergens are used. A positive control (histamine) and negative
control (diluents) are also used. In general practice, a drop of each
common inhalant allergens as well as the positive and negative
controls are placed on the skin of forearm pricked by a sterile lancet
needle specific for each allergen and left for 15 minutes. A positive
result is confirmed by a skin wheal of >2 mm greater than that seen by
the diluents. Bronchial and nasal provocation tests can be also
performed if skin prick and RAST tests were negative. A certain
concentration of histamine or metacholine is administered to the
patient that causes 20% drop in FEV1. Nasal smears are undertaken to
estimate the number of eosinophil in the nasal discharges. A cotton
bud is placed in each nostril and the mucosa is scraped with a film
rolling movement and then the cotton bud are gently spread into a
microscopic slide and stained and the cells are counted. Positive result
is determined if more than 10% of the stained cells are eosinophils.
The other test is radio allergosorbent (RAST) or serum allergen
specific IgE levels. The allergens are covalently bounded to cellulose. If
the patient’s serum contains IgE antibodies, it will react to its specific
allergen complex. Non-specific IgE are washed off and then specific
anti IgE conjugate is added to the IgE bound allergen with a
fluorescent marker. The fluorescence of each complex is measured by
the machine and printed out. Any reading above 0.35 ku/l is
considered as positive. Bronchodilator challenge test using
spirometery is also used to check the presence of reversible airway
obstruction.The patient should take a deep breath applying a nose clip,
and then exhale the air for six seconds as fast and hard as he can
through the mouthpiece that is connected to the machine by a tube,
finally the machine measures the total amount of air exhaled (FVC)
and how much air exhaled in one second (FEV1) and the results are
printed out Asthmatic have FEV1/ FVC value of 0.7 L or 70% before
the test, but after doing it they show an increase in FEV1 by at least
12% and at least 200 mL in FVC pointing to reversible airflow
obstruction.

COPD
Definition, classification, and diagnosis:
COPD is defined as a "progressive and irreversible airflow
obstruction of the peripheral airways”. COPD has three main
components including chronic obstructive broncholitis with fibrosis
and small airway blockage, emphysema with the enlargment of
airspaces and damaged lung parenchyma, and chronic bronchitis that
is mucus hyper-secretion. Smoking, air pollution (poisonous gases,
diesel exhust, ozone, and PM), and occupational exposure to dust are
the main causes for the development of COPD. Smoking accounts for
>95% of all cases as being a risk factor Symptoms of COPD include
productive cough, sputum, and most importantly shortness of breath.
GOLD (Global Intiative for Obstructive Lung Disease) classifies the
severity of COPD into 4 stages according to spirometery.All four
stages have a ratio of FEV1/FVC around 70% or 0.7 L while the exact
value is dependent on age, height, weight, sex, and ethnicity. Stage I
(mild) is charactarized by FEV1>80%,stage II (moderate) FEV1 is
between 50%-80%, stage III (severe) FEV1 within 30%-50%, and stage
VI (very severe) FEV1<30% or<50% plus chronic respiratory failure.
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Spirometery as well as mediacl history have been used in the diagnosis
of COPD. Confirm the diagnosis of COPD involves looking into its
irrversibility component. Performing bronchodilator challenge test in
COPD patients (FEV1/FVC 0.7 L or 70%) shows no increase by 12% in
FEV1 or 200 mL in FVC.Its prevalence is very high in smokers and exsmokers, people over 40 years of age, and more specifically males.

Differences between asthma and COPD:
Although inflammation is present in both asthma and COPD, there
are some markeddifferences in inflammatory cells and mediators,
limitation of airflow, parenchymal integrity, (BHR), response to antiinflammatory therapy, and onset of symptoms Barnes et al. [1]. In
asthma, the main cells recruited are TH2 (CD4+) lymphocytes,
eosinophils, and mast cells while in COPD Tc1 (CD8+) lymphocytes,
neutrophils, and macrophages are involved in the inflammatory
response. The main mediator released in asthma is histamine that is
absent in COPD. TH2 lymphocytes release IL-4 that causes the
production of IgE from B-lympocytes while Tc1 produce INF-γ
inhibiting IgE synthesis. Airflow limitation is largely reversible in
asthma, but it is largely irreversible in COPD. The lung parenchyma in
asthma is intact as compared to COPD, which is badly destructed.
BHR is significant feature of asthma with its being variable (small)
component of COPD. Asthmatics respond very quickley to steriod
traetment in comparison to the presence of steriod resistance in
COPD patients. Asthmatics have almost normal lung function with
treatment compared to everyday symptoms of COPD even though the
use of bronchodilaros and smoking cessation [1]. Onset of asthma is
very early during childhood while COPD develops in smokers and exsmokers in their mid 40s [1]. Histopathology studies showed that the
inflammation in COPD affects the peripheral airways (bronchioles)
and lung parenchyma whereas the whole airway without the
involvment of parenchyma is inflammed in asthma.

Nitric Oxide
Discovery of importance
NO is the most widely studied exhaled marker of airway
inflammation). Interest in nitrate has been old enough when Alfred
Nobel invented the dynamite in 1863. He eventually died of angina
pectoris from the work on it. In 1916, dietary studies showed that the
body is internally producing nitrate with the source being L-arginine
amino acid. In 1980, research within the cardiovascular field not the
pulmonary area showed the significance of NO. They suggested that
the stimulation of endothelium by acetylcholine caused the release of a
substance that easily diffuses and targets smooth muscle cells of the
arteries causing their vasodilatation in isolated arterial lungs.Removal
of that substance stopped such relaxation. They named it EDRF,
endothelium derived relaxing factor. In 1986, EDRF was recognized as
NO because of their similar properties.

Physical and chemical properties
Physical and chemical properties of NO are, as the following. At
room temperature, it is colorless gas and in the absence of O2, it
dissolves in water. It is made of one nitrogen and 1 oxygen atoms so it
is a small molecule. It has a short half-life depending on its
concentration and physio-chemical environment. It has an odd
number of electrons. This property makes it a free radical that can
diffuse easily from its site of formation being highly reactive with
many other atoms and free radicals in biological systems. It reacts with
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O2 forming nitrate and nitrite. In the presence of superoxide anion
(O2-), NO can react with it forming (OONO-), a toxic anion causing
lipid peroxidation impairing the cell membrane resulting in cell death
and DNA destruction. It also binds to thiols producing S-nitrosothiols
such as S-nitrosocysteine and S-nitrogluththione. They act as NO
donors when needed. NO have high affinity for the ferrous (Fe2+) part
of the haemoproteins such as haemoglobin, myoglobin, cytochrome C
and soluble guanylatecyclase leading to the production of nitrosyl
substances.

Significance in biological systems
NO is a critical molecule as it has a pivotal role in
neurotransmission, regulationof vasodilation, pulmonary host defence
by acting as bacteriostatic or bactericidal, cell mediated immunity,
ciliary beat frequency, mucus secretion, plasma exudation, and as a
marker of inflammation. NO is released from inhibitory nonadergenic non-cholinergic nerves causing the bronchodilator effect in
human airways. Smooth muscles are present in vascular endothelium
and the bronchi so NO regulates pulmonary arterial vasoconstriction.
The use of NOS inhibitors proved to reduce the vasodilatory response
in pulmonary arteries in vivo and in animal studies. Cells that produce
NO are fibroblasts, endothelial and epithelial cells, keratinocytes,
chondrocytes, monocytes/macrophages, APCs, natural killer (NK)
cells, eosinophils, and mast cells. Low levels of NO are essential for
normal body functioning, but there is disease conditions that alter NO
level to be high. A study on normal mice showed that epithelial cells
express minor levels of NOS 2 that is responsible for NO release in
exhaled air. With the proliferation of inflammatory cytokines, the
induced NOS isoform is expressed causing the increased eNO in
asthmatics. In asthma, the increased expression of NOS 2 in airway
epithelial cells is linked to elevated transcription process through
transcription factor (STAT 1) and nuclear transcription factor (NF κB)
withthe increased presence of L-arginine. The major cells contributing
to the increased NO levels expressing iNOS are epithelial cells,
macrophages, and eosinophilsand those origins are relevant to
asthma.Astudy measured the variability of eNO among asthmatics
compared to normal subjects. They found that eNO was elevated in
asthmatics compared to normal controls. It was higher in moderatesevere asthmatics than mild and normal people. Their finding
suggested that eNO was not significantly different in mild asthmatics
than normal controls. They also showed that there is a decreased
expression of IFN-γ in moderate-severe asthmatics. This is because
increased eNO level inhibits Th1 cytokine expression. A study by
Taylor et al. showed that cloned murine Th1 cells activated by antigens
were able to express iNOS and caused NO production. Further NO
production inhibited Th1 cell proliferation and so IL-2 and IFN-γ
release. The level of eNO is altered within the respiratory tract. The
level of eNO from the URT is (200-1000 p.p.b. (parts per billion)),
from the sinuses it is (1000-30000 p.p.b.), and the LRT it is very low
about (1-9 p.p.b.). The paranasal sinuses have high eNO level as there
is an evidence for continuous expression of NOS 2.

Exhaled nitric oxide measurement
eNO measurement requires a single breath exhalation technique. In
1997, eNO was found to be inversely proportional to expiratory flow
rate in what is called flow dependence. Therefore, high flow rate
reduces eNO while low flow rate increases eNO. There was a need to
standardize the flow rate so the European Respiratory Society (ERS)
and the American Thoracic Society (ATS) identified a certain flow rate
for eNO measurements and that is 50 ml/s. As discussed previously
Chem Sci J
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NO is released from the URT and LRT and detecting lung
inflammation should not include the nasal NO. eNO measurement
ensures the exclusion of nasal NO through making the subject inhale
to total lung capacity without a nose clip followed by exhalation at a
constant flow rate of 50 mL/s against resistance with positive mouth
pressure that should range between 5-20 cm H2O closing the velum
and so no NO interrupts the measurement. eNO was found to be
significantly correlated with other markers of inflammation such as
airway hyper-responsiveness, sputum and blood eosinophil, and total
and specific IgE.
There are many factors affecting eNO level. Age was proved to
affect the eNO level. eNO was seen to increase in children with age.
Also, sex affects eNO level. A recent study conducted showed that
eNO levels are 25% higher in males than females (males: 15.3 ppb
[95% C.I.: 14.3-16.3] vs. females: 11.6 ppb [95% C.I.: 11.0-12.4];
p<0.0001). In this study, atopic individuals were found to have
increased eNO level by 60%. Another study showed that normal values
for adult exhaled nitric oxide are 2.6- 28.8 p.p.b or 2.6- 28.8 nl/l for
males and 1.6-21.5 p.p.b for females. Thus, differences between males
and females account also for normal eNO values. Breath-holding, low
exhalation flow rate, high ambient NO, nasal NO, nitrate rich food,
inhaled or ingested L-arginine, exercise are factors causing the
increased eNO. On the other hand, high exhalation flow rate, sputum
induction, bronchial provocation tests, spirometery, NOS inhibitors,
use of corticosteroids, oral leukotriene antagonists, and smoking and
passive smoking are related to reduced eNO level. Taking into
accountthe previous factors, Aerocrinecompany in Sweden designed
many NO analyzers such as NIOX NO monitoring system and NIOX
MINO hand held device using the ERS/ATS guidelines. They designed
those machines as the patient inhales NO free air through a disposable
mouth piece with flow dependency on 50 ml/s preventing
contamination from nasal NO and ambient NO. eNO level is defined
as a 3-second NO plateau at the end of exhalation and the patients can
ensure a valid result by getting visible (screen) and audible
(continuous sound) feedback.eNO should be measured prior to
exercise, sputum induction, bronchial provocation tests, and
spirometery. Some respiratory diseases may also increase or decrease
eNO level while others show variable changes.
There are many advantages for eNO measurement. It has high
reproducibility. Khartinovo and colleagues showed high
reproducibility using the NIOX NO monitoring system with a
standard deviation of 2.1 ppb. High reproducibility of eNO in both
children and adults allows the medical technician to repeat the
measurement twice with more reliable results instead of three
exhalations as compared to spirometer. Another study by Alving et al.
showed high success rate of (≥ 84%) using the NIOX and NIOX
MINO machines in clinical (with practitioner help) and home set
(without). This demonstrates easy use of the machine by patients
especially the hand held NIOX MINO. eNO has been used in the
diagnosis of asthma. It predicts future asthma or asthma exacerbations
especially in patients with subclinical symptoms such as normal
function tests, negative bronchodilator tests, and low sputum ECP
(eosinophilic cationic protein) concentrations having high eNOlevel.
Harkins et al. looked into the use of eNO as a monitoring tool for
predicting future asthma exacerbations. They studied 22 moderatesever asthmatics and demonstrated that after 2 weeks of initial
appointment in a routine clinic visit some of them had exacerbations
with a high mean eNO (29.67 ppb ± 14.48) compared to those without
exacerbation, who had mean eNO value of (12.92 ppb ± 5.17)
(р=0.002). eNO was found in the study to be statistically significant
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(р=0.031) compared to FEV1 (р=0.56) in the prediction of future
asthma exacerbations. Because eNO is a non-invasive and cost
effective method, it can be used to monitor a large populat. eNO has
been used in measuring the effectiveness of anti-inflammatory drug. In
addition, eNO is very sensitize to corticosteroid treatment as it
decreases after 6 hrs of a single use of this treatment or 2-3 days even
reaching the maximum level after 2-4 weeks of therapy. Shome et al.
study concluded that eNO is declining in moderate-severe asthmatics
with steroid therapy and by 4 weeks it was not significantly different
from mild asthmatics or healthy controls. In a study conducted by
Silkoff et al. 62 patients (33 children and 32 adults) with uncontrolled
asthma were assessed to observe the effect of steroid treatment on the
level of eNO. eNO were recorded at visit 1 and visit 2. The results for
both age groups showed high significant decreased in eNO from visit 1
to visit 2 with a mean standard deviation percentage change in eNO
levels of -50.5% ± 31.41% (P<0.001). Reductions in steroid intake
result in an increase in eNO level by 40% and 100% after 2 and 4 weeks
respective. High sensitivity of eNO to steroid treatment helps in
adjusting the dose of corticosteroids because high doses harm the
patients. In some cases of persistent asthma symptoms, eNO remains
high despite the use of corticosteroids as being a marker indicating
steroid resistance. Also, eNOlevel respond quickly to any changes in
the airways before other parameters change such as lung function tests
and sputum eosinophil being a good sign for loss of control. The
increase in eNO is accompanied by reduced lung function tests and
increased asthma related symptoms leading to exacerbations. Sputum
induction is believed to be invasive and difficult to perform in
children. Lung function and bronchial provocation tests have
limitations because they are not directly related to airway
inflammation and can be easily affected by bronchodilators
(Khartinovo and Barnes, 2001). eNO is directly related to the
inflammatory response as it is released by many inflammatory cells.
Both of them take a significant amount of time to change and they are
not able to assess the effect of various steroid doses. Using NIOX
analyzers does not require that much staff training as it operates
automatically.
Because asthma is characterized by eosinophilic inflammation, it
can be detected with elevated eNO levels. In stable COPD, the
inflammation is mainly neutrophilic suggesting lower levels of eNO
than smokers and nonsmokers with asthma not different from normal
subjects being less likely to respond to steroids (Khartinovo and
Barnes, 2001). Chronic cigarette smoking decreases eNO. This is
because increased NO in cigarettes down regulate NOS and oxidants
in the smoke inactivates NO release. This may responsible for the
decreased eNO in COPD patients. Maziak et al. showed that eNO is
higher in unstable COPD patients than current smokers with COPD,
ex-smokers with COPD, and smokers with chronic bronchitis without
airflow obstruction (12.7 ppb ± 1.5 ppb) (p<0.01. eNO were higher in
smokers with COPD compared to smokers with chronic bronchitis
(4.3 ppb ± 0.5 ppb vs. 2.5 ppb ± 0.5) (p<0.05) and even higher in exsmokers with COPD (6.3 ppb ± 0.6 ppb) (p<0.01). eNO also was high
in COPD patients under steroid treatment (most are severely ill) in
relation to steroid naïve COPD patients (8.2 ppb ± 1.2 ppb vs. 5 ppb ±
0.4 ppb) (p<0.05). There was not a significant difference between
COPD steroid naïve and COPD steroid treated in terms of eNO
indicating steroid resistance in COPD. In patients with severe disease,
the increase in eNO far much exceeds its decrease due to smoking.
Severe COPD cases in the previous study (FEV1<35%) showed high
eNO level compared to stable COPD. Thus, it can be used to assess
disease activity in COPD and monitor response to steroid treatment.
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This is because some COPD patients with concomitant asthma exhibit
high eNO levels.

Objectives
To compare the significance of eNO and other available markers
(serum specific IgE, and relative blood eosinophil) in achieving a clear
diagnostic criteria between inflammatory respiratory diseases aiming
at better management and control.
To establish a reliable objective marker for diagnosis and
monitoring of asthma. To determine the contribution of allergy in the
etiology of asthma.

Methods
Participants: 76 subjects were enrolled in the study. They were 23
asthmatics, 20 with allergic rhinitis, 10 with COPD, and 17 healthy
individuals. The age range was 7-60 years both males and females.
They were randomly selected from different ethnic backgrounds.
Patients were attending the outpatient clinics at a local hospital within
Abu Dhabi (especially those in the ENT, pediatric, and medical
clinics). They were referred to the allergy clinic to be informed more
about the study. Asthmatics were pre-diagnosed according to the
GINA guidelines. Allergic rhinitis patients were already seen by ENT
consultants or by an allergist. COPD patients were also pre-diagnosed
by chest physicians. The final group was the healthy controls, who
were hospital staff or patients who were visiting the clinic for routine
annual medical checkup.
A case study sheet was prepared for each patient pertaining to
personal and demographic information, family history of disease,
symptoms occurrence, provoking factors, and social factors. Informed
consent was obtained from all participants and also an ethical approval
was granted from the hospital’s IRB. Patients with chronic debilitating
diseases such as diabetes mellitus, liver diseases, cancer and those
taking immune-suppression therapy were excluded from the study. All
patients were assessed for eNO level, relative blood eosinophil count,
and RAST tests.

Exhalednitric oxide (eNO) level
The patient’s eNO level was measured by using the NIOX MINO®
portable machine (Aerocrine, Sweden). The patient should empty his
lungs and then inhale from the machine until full lung capacity and
exhales against a constant positive counter pressure of 10-20 cm H2O
to ensure a flow rate of 50 ml/s for 10s preventing nasal contamination
as well. The machine displays a reading determining the content of
NO in the exhaled air. Normal values based on the previous flow rate
are 1.6-28.8 p.p.b for both adult males and females and the upper limit
for children aged 4-17 is 25 p.p.b.

Specific IgE test (RAST)
Specific IgE antibodies in patient’s serum could be assessed using
the Immuno CAP Flourenzymatic immunoassay technique with the
use of UNI CAP 100Э machine. The machine with the allergens is
provided by (Pharmacia Diagnostis, Uppsala, Sweden) (Ownby, 1993).
The allergens are covalently bounded to a cellulose solid phase called
ImmunoCAPs. Patient’s serum, controls, the reagents, and the
ImmunoCAPs are loaded into their specific locations. The machine
transmits a specific quantity of serum and the controls to the
ImmunoCAPs initiating the first incubation. If the serum includes
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specific IgE, it will combine with its specific allergen in the
ImmunoCAPs. After washing to remove any unbounded IgE, specific
anti-IgE conjugate (with a fluorescent detector) is added to the
ImmunoCAPs starting the second incubation. Finally, a stop solution
is transferred and the fluorescence of each ImmunoCAP is assessed by
the machine. Any reading above 0.35 ku/l is considered as positive
(Ownby, 1993).

Relative blood eosinophil count
WBC could be analyzed using Automated Hematology Analyzer
machine (XE-2100) which gives complete blood count mainly WBC
(NEUT, LYMPH, MONO, BAS, EOS), RBC, PLT, HGB. The required
blood sample volume in the tube is 1 mL or more. More than 4%
eosinophil was reported as abnormal.

Data Analysis

Figure 2: Comparison of parameters between groups.

All data was analyzed using SPSS version 21 (Chicago, USA. the
analysis using this software revealed the correlations between eNO and
other factors (age and blood eosinophil).

Clinical state

Results
The results indicated that there was no significant difference in
mean values between healthy non-smoker males (N=4) and healthy
non-smoker females (N=13) in the level of eNO (Figures 1 and 2).
Results from Table 1 showed that 74% of asthmatics had high eNO
compared to those with COPD, allergic rhinitis, and healthy groups,
who had 10%, 25%, and 6%, respectively. Percentage of asthmatics
having high blood eosinophil was 52%, COPD was 0%, AR was 17.6%,
and healthy was 30%. RAST test positivity to one or more inhalant
allergens showed no difference between asthmatics (91%) and allergic
rhinitis patients (75%) in contrast to the case of COPD (30%) and
healthy (29.4%). Figure 2 compares the three parameters between the
four groups. Results also revealed that eNO and age were negatively
associated, [-0.26], p<0.05. Also, eNO and eosinophil were positively
associated [0.46], p<0.01. The level of eNO was significantly high
among asthmatics compared to the other groups. This significance had
an F value of 20.02, p<0.01. The eNO levels demonstrated that there
was a difference between groups.

Figure 1: eNO levels in healthy controls by means.
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% with high Exhaled % with
%
with
nitric oxide
positive RAST
Raised blood
(eNO)
eosinophilia
No

%

No

%

No

%

Healthy (N=17)

1

6

3

17.6

5

29.4

Asthmatics
(N=23)

17

74

12

52

21

91

COPD (N=10)

1

10

0

0

3

30

rhinitis 5

25

6

30

15

75

Allergic
(N=20)

Table 1: The results indicated that there was no significant difference
in mean values between healthy non-smoker males (N=4) and healthy
non-smoker females (N=13) in the level of eNO (Figure 1 and 2).

Discussion
Asthma is defined as a chronic airway inflammation characterized
by reversible airflow obstruction, yet most physicians still rely on
subjective measures (as frequency of attacks of shortness of breathes)
in the diagnosis and monitoring of asthma. These measures are mostly
inconsistent and do not reflect the real inflammatory pathology. In
this preliminary study, an attempt was made to find an objective
parameter to be used as a reliable marker for asthma diagnosis and
monitoring.
Three clinical groups of patients; those with asthma; those with
allergic rhinitis and those with COPD as well as a healthy group were
investigated. Three laboratory tests were used, the exhaled Nitric oxide
level, the percentage blood eosinophilia and the allergic sensitization
tests. The results of this preliminary study clearly showed that exhaled
nitric oxide level is higher in asthmatic patients compared to healthy
individual and it is relatively higher than other clinical groups with
respiratory inflammation. Blood eosinophilia does not show such
significant difference among different groups. This is because blood
eosinophilia is a general parameter for allergy and is not specific for
respiratory allergy while eNO level is specific for airway inflammation.
Moreover, blood eosinophilia is affected by many other factors such as
intestinal infestation, eczema etc. while eNO is not. Most studies have
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demonstrated that NO level in the exhaled air corresponds to the
extent of eosinophilic airway inflammation (Alving et al., 2006). eNO
shows better correlation with sputum eosinophilia rather than with
blood eosinophilia.
We found that in patients with COPD the levels of eNO were not
very high, this is because inflammation in COPD is characterized by
neutrophils infiltration rather than eosinophils. These patients are
known to have poor response to steroids therapy, in contrast to
asthmatic patients with high eNO levels, who are good responders.
Regarding the degree of allergic sensitization as measured by RAST
test, we found that asthmatic patients as well as allergic rhinitis
patients showed a higher degree of positive allergic sensitization to one
or more inhalant allergens as compared by healthy individual.
However, RAST test is not specific for asthma as it can be positive in
other allergic disorders (e.g. allergic rhinitis, atopic eczema, food
allergy etc.). Moreover, there were few asthmatics, which showed
negative RAST test. In this study, we found that around 87% of our
asthmatics had high positive sensitivity to dust mite allergens. This
shows that allergy to inhalant allergens in UAE contributes greatly to
the etiology of asthma and that allergic asthma is more common in
Abu Dhabi population than non-allergic (intrinsic) asthma. This may
be due to the type of housing in Abu Dhabi, which is closed system
ventilation with door to door carpet fitting, in addition to, the high
humidity all over the year due to its location near the Arabian Gulf.
These factors increase indoor dust mite concentrations, which tend to
accumulate mainly on bed covers, carpets, furniture, and children’s
soft toys and cause sensitization of susceptible persons. Moreover,
there is an enormous increase in construction projects especially in
Abu Dhabi and Dubai, hence increasing air pollution and favoring the
risk of sensitization. It is known that as humidity increases reaching
75% and under room temperature of 25°C, droppings of mites become
suspended in the air and when inhaled by genetically predisposed
persons cause asthma or allergic rhinitis symptoms. Most of patients
are treated by immunotherapy to boost their immune system making
it less responsiveness to dust when encountered over and over.
Another important finding from this study is that some allergic
rhinitis patients had high eNO levels without any symptoms of
asthma. This is a threatening indication for future development of
asthma and the physicians should be aware of it in order to prevent
progression. Therefore, the allergist should describe intranasal as well
as inhaled or oral corticosteroids for treating both conditions together.
Thus, it is apparent that eNO can be used as a biomarker for
assessing the extent of airway inflammation and help in the diagnosis
and monitoring of asthma even before the onset of clinical symptoms
of airway obstruction. It can be used to differentiate asthma from
other respiratory disorders especially COPD, which does not show
very high levels of eNO.
Our results demonstrated that the high eNO level in asthmatic
patients dropped markedly and rapidly in response to steroid therapy
and thus, could be used to monitor the response of patient to
treatment and guide its dose and duration. It is far superior to the
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traditional methods that have been used for monitoring asthma such
as spirometery and sputum induction, which as discussed previously
in the introduction, require longer time to show the changes (Scientific
Backgrounder, 2003). Furthermore, spirometry can be sometimes
normal (during the quite reversible state) in spite of, ongoing airway
inflammation while eNO level will remain high even in sub clinical
state as it reflects exactly the state of airway pathology. Corticosteroids
treatment has a direct effect on switching off the cascade of
inflammatory process and thus will lower eNO level immediately. In
COPD, inflammation is not suppressed by corticosteroids as it is
produced by other mechanisms. The biomarker eNO is an applicable
measurement to all age groups and easy to perform especially among
children.
Levels of eNO were negatively correlated with age, p<0.05. This
correlation is not expected as children grow up, their eNO levels
increase. It can be assumed that the small sample size in this study as
only few children were included compared to the adult group may not
precisely reflect the age effect. If larger sample was studied, it would be
more representative. The effect of gender on eNO levels was not
significantly different between healthy non-smoker males and females
though literature proved the opposite. One study by Taylor et al. has
shown a significant gender related difference in eNO levels even after
controlling the other factors such as smoking, and atopy. This can be
also due to the small sample size studied. Further investigations with
larger study samples are needed to provide concrete evidence. Also
longitudinal studies with follow up after therapy would be more
informative. However, this preliminary study had demonstrated the
applicability of eNO measurement as a monitoring tool for airway
inflammation in clinical practice in the UAE.
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